Evidence map›Paper›PMID 40321218›Full record

ArticlebioRxiv : the preprint server for biology2025

Methylation reprogramming associated with aggressive prostate cancer and ancestral disparities.

Jenna Craddock, Pavlo Lutsik, Pamela X Y Soh, Melanie Louw, Md Mehedi Hasan, Sean M Patrick, Shingai B A Mutambirwa, Phillip D Stricker, Hagen E A Förtsch, HEROIC PCaPH Africa1K and 3 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Jenna CraddockSchool of Health Systems and Public Health, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa.
Pavlo LutsikDivision of Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0001-9383-8555
Pamela X Y SohAncestry and Health Genomics Laboratory, Charles Perkins Centre, School of Medical Sciences, Faculty of Medicine and Health, University of Sydney, Camperdown, NSW, Australia.
Melanie LouwNational Health Laboratory Services, Johannesburg, South Africa.
Md Mehedi HasanAncestry and Health Genomics Laboratory, Charles Perkins Centre, School of Medical Sciences, Faculty of Medicine and Health, University of Sydney, Camperdown, NSW, Australia.
Sean M PatrickSchool of Health Systems and Public Health, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa.
Shingai B A MutambirwaDepartment of Urology, Sefako Makgatho Health Science University, Dr George Mukhari Academic Hospital, Medunsa, Ga-Rankuwa, South Africa.
Phillip D StrickerDepartment of Urology, St Vincent's Hospital and Private Clinic, Darlinghurst, NSW, Australia.
Hagen E A FörtschWindhoek Central Hospital, Windhoek Khomas, Namibia.
HEROIC PCaPH Africa1K
M S Riana BornmanSchool of Health Systems and Public Health, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa.
Clarissa GerhaäuserDivision of Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0002-5792-3901
Vanessa M HayesSchool of Health Systems and Public Health, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa.ORCID 0000-0002-4524-7280

Funding

Genomic bases for African geo-ethnic prostate cancer health disparityR01CA285772 · NCI · UNIVERSITY OF SYDNEY · PI Vanessa Marie Hayes · 2024 to 2026
$1.5M
NCI NIH HHS R01 CA285772
6 · The paper itself

Abstract

African men are disproportionately impacted by aggressive prostate cancer (PCa). Key to this disparity both genetic and environmental factors, alluding to epigenetic modifications. However, African-inclusive prostate tumour DNA methylation studies are lacking. Assembling a multi-geo-ancestral prostate tissue cohort, including men with (57 African, 48 European, 23 Asian) or without (65 African) PCa, we interrogate for genome-wide differential methylation. Overall, methylation appears to be driven by ancestry over geography (152 southern Africa, 41 Australia). African tumours show substantial heterogeneity, with universal hypermethylation indicating epigenetic silencing, encompassing PCa suppressor genes and enhancer-targeted binding motifs. Conversely, African tumour-associated heterochromatic hypomethylation suggests permissive chromatin remodelling, with developmental pathway activation via enhancer targets. Taken together, we show methylation aberrations favour metastatic growth, genomic instability and disease aggressiveness in African tumours, which we hypothesise is driven by extensive plasticity of intergenic regulatory regions.

Indexed as

African ancestrydifferential methylationhealth disparityprostate tumours

Identifiers

PMID40321218
PMCPMC12047885

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.